A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury

@article{Singh2021ASR,
  title={A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury},
  author={Ambrish Singh and Salman Hussain and Vijay Kher and Andrew J. Palmer and Matthew D Jose and Benny Antony},
  journal={Expert Review of Pharmacoeconomics \& Outcomes Research},
  year={2021},
  volume={22},
  pages={27 - 35}
}
ABSTRACT Introduction Though cost-effectiveness analyses (CEAs) have evaluated continuous renal replacement therapy (RRTs) and intermittent RRTs in acute kidney injury (AKI) patients; it is yet to establish which RRT technique is most cost-effective. We systematically reviewed the current evidence from CEAs of CRRT versus IRRT in patients with AKI. Areas covered PubMed, EMBASE, and Cochrane databases searched for CEAs comparing two RRTs. Overall, seven CEAs, two from Brazil and one from US… 
1 Citations

Akut böbrek yetmezliğinde hiperüriseminin rolü

Amaç: Akut böbrek yetmezliği (ABY) yoğun bakım hastalarında mortaliteyi etkileyen en önemli faktörlerden biridir. Bu çalışmanın amacı, ürik asit düzeyleri ile akut böbrek hasarı (AKI) / ABY arasında

References

SHOWING 1-10 OF 43 REFERENCES

Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury

TLDR
Assessment of differences between CRRT and IRRT regarding important clinical outcomes and cost-effectiveness show that initial CRRT is associated with higher rates of renal recovery and transferability of the economic analyzes to the German health care system is limited.

Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis

TLDR
Among AKI survivors, initial treatment with IRRT might be associated with higher rates of dialysis dependence than CRRT, however, this finding largely relies on data from observational trials, potentially subject to allocation bias, hence further high-quality studies are necessary.

Economic evaluation of different treatment modalities in acute kidney injury.

  • D. De SmedtM. ElseviersR. LinsL. Annemans
  • Medicine, Political Science
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
This study has indicated that the most expensive treatment (CRRT) associated with an incremental cost of approximately €7920 generates only a minor non-significant increase in QALYs of 0.07 compared with IRRT, which seems to be the preferred treatment strategy from a health economic perspective.

Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients

TLDR
Initial CRRT is cost-effective compared with initial IRRT by reducing the rate of long-term dialysis dependence among critically ill AKI survivors.

Renal replacement therapy in patients with acute renal failure: a systematic review.

CONTEXT Acute renal failure requiring dialytic support is associated with a high risk of mortality and substantial morbidity. OBJECTIVES To summarize current evidence guiding provision of dialysis

Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury

TLDR
The SHARF study showed that the higher mortality expected in AKI patients receiving RRT versus conservative treatment can not only be explained by a higher disease severity in the RRT group, even after multiple corrections.

Cost of Acute Kidney Injury in Hospitalized Patients

TLDR
In the United States, AKI is associated with excess hospitalization costs and prolonged LOS and warrants further attention from hospitals and policymakers to enhance processes of care and develop novel treatment strategies.

The Economic Consequences of Acute Kidney Injury

TLDR
Light is shed on an opportunity for hospitals and policymakers to develop new care processes for patients with AKI that have the potential to yield substantial cost savings and motivate scientists and entrepreneurs to pursue a variety of innovative therapeutic strategies to combat AKI in the near term.